HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $73 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Legend Biotech (NASDAQ:LEGN) and maintained a price target of $73.
August 12, 2024 | 10:41 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Legend Biotech and maintained a price target of $73.
The reiteration of a Buy rating and a maintained price target of $73 by a reputable analyst firm like HC Wainwright & Co. is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100